Genprex (FRA:2DE1) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2DE1 Genprex Inc FRA:2DE1
35 GF Score
Price €3.96
! 1 Warning Sign
View Full Analysis

What is Genprex Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:2DE1 vs MLEC, LIMN, ADIL: Short Interest Comparison

For the Biotechnology subindustry, Genprex's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genprex Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Short Interest distribution charts can be found below:

* The bar in red indicates where Genprex's Short Interest falls into.


FRA:2DE1
35GF Score
Genprex Inc FRA:2DE1
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genprex Business Description

Other Exchanges GNPX:USA0A8I:UK
Address 3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
35GF Score

Get the complete analysis for FRA:2DE1

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price